Plasma protein biomarkers for the prediction of CSF amyloid and tau and [18F]-flutemetamol PET scan result
<strong>Background:</strong> Blood biomarkers may aid in recruitment to clinical trials of Alzheimer’s disease (AD) modifying therapeutics by triaging potential trials participants for amyloid positron emission tomography (PET) or cerebrospinal fluid (CSF) Aβ and tau tests. <strong&g...
Main Authors: | Westwood, S, Baird, AL, Hye, A, Ashton, NJ, Nevado-Holgado, AJ, Anand, SN, Liu, B, Newby, D, Bazenet, C, Kiddle, SJ, Ward, M, Newton, B, Desai, K, Hehir, C, Zanette, M, Galimberti, D, Parnetti, L, Lleó, A, Baker, S, Narayan, VA, Van Der Flier, WM, Scheltens, P, Teunissen, CE, Visser, PJ, Lovestone, S |
---|---|
Formato: | Journal article |
Publicado: |
Frontiers Media
2018
|
Títulos similares
-
Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result
por: Sarah Westwood, et al.
Publicado: (2018-12-01) -
The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
por: Westwood, S, et al.
Publicado: (2017) -
New CSF biomarkers on the block
por: Charlotte E Teunissen, et al.
Publicado: (2016-09-01) -
Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Rosha Babapour Mofrad, et al.
Publicado: (2019-12-01) -
Determining the molecular pathways underlying the protective effect of non-steroidal anti-inflammatory drugs for Alzheimer's disease: A bioinformatics approach
por: Nevado-Holgado, A, et al.
Publicado: (2016)